Rituximab: modes of action, remaining dispute and future perspective
Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
Future Medicine Ltd.
2014
|
| Subjects: |